{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:57:17Z","timestamp":1791165437865,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.medine.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T08:36:13Z","timestamp":1666168573000},"page":"700-710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of Acinetobacter baumannii severe infections"],"prefix":"10.1016","volume":"46","author":[{"given":"R.","family":"Reina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Le\u00f3n-Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garnacho-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2022.08.007_bib0005","unstructured":"OMS. La OMS publica la lista de las bacterias para las que se necesitan urgentemente nuevos antibi\u00f3ticos. Available from: https:\/\/www.who.int\/es\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"10.1016\/j.medine.2022.08.007_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.medine.2022.08.007_bib0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nrmicro1789","article-title":"An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii","volume":"5","author":"Dijkshoorn","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.medine.2022.08.007_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-030-16373-0_5","article-title":"Mechanisms of polymyxin resistance","volume":"1145","author":"Moffatt","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.medine.2022.08.007_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/antibiotics9040205","article-title":"Acinetobacter baumannii resistance: a real challenge for clinicians","volume":"9","author":"V\u00e1zquez-L\u00f3pez","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.medine.2022.08.007_bib0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis","volume":"79","author":"Mohd Sazlly Lim","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0035","first-page":"465","article-title":"How should we treat acinetobacter pneumonia?","volume":"25","author":"Amaya-Villar","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.medine.2022.08.007_bib0040","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1111\/jam.15130","article-title":"Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review","volume":"131","author":"Nguyen","year":"2021","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.medine.2022.08.007_bib0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1378\/chest.09-0465","article-title":"Does biofilm formation play a role in ventilator-associated tracheobronchitis?","volume":"136","author":"Drinka","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.medine.2022.08.007_bib0050","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/cc13940","article-title":"Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia","volume":"18","author":"Nseir","year":"2014","journal-title":"Critical Care"},{"key":"10.1016\/j.medine.2022.08.007_bib0055","first-page":"532","article-title":"Antibiotic treatment of ventilator-associated tracheobronchitis: to treat or not to treat?","volume":"20","author":"Craven","year":"2014","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.medine.2022.08.007_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CCM.0000000000000771","article-title":"The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis","volume":"43","author":"Valachis","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medine.2022.08.007_bib0065","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia. IASIS trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.medine.2022.08.007_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/cid\/cis385","article-title":"Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection","volume":"55","author":"Lee","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2014.01.018","article-title":"Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/QCO.0000000000000518","article-title":"Managing Acinetobacter baumannii infections","volume":"32","author":"Garnacho-Montero","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0085","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","article-title":"Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet?","volume":"48","author":"Tran","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2022.08.007_bib0090","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Colistin Breakpoints \u2013 guidance document 2021. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_documents\/Colistin_guidance_2021.pdf."},{"key":"10.1016\/j.medine.2022.08.007_bib0095","unstructured":"Clinical and Laboratory Standards Institutes. Performance standards for antimicrobial susceptibility testing. Available from: https:\/\/clsi.org."},{"key":"10.1016\/j.medine.2022.08.007_bib0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medine.2022.08.007_bib0105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jac\/dkm357","article-title":"Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review","volume":"60","author":"Zavascki","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0115","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkl512","article-title":"In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates","volume":"59","author":"Owen","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0125","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dkn425","article-title":"In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae","volume":"62","author":"Poudyal","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0130","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1128\/AAC.00903-09","article-title":"Pharmacokinetic\/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model","volume":"54","author":"Bergen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/ja.2015.127","article-title":"Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii","volume":"69","author":"Tran","year":"2016","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.medine.2022.08.007_bib0140","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/jac\/dkv135","article-title":"Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two \u2018old\u2019 antibiotics\u2014polymyxin B and chloramphenicol","volume":"70","author":"Abdul Rahim","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0145","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/AAC.49.9.3624-3630.2005","article-title":"Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa","volume":"49","author":"Tam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0150","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0155","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkr007","article-title":"Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae","volume":"66","author":"Meletis","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0160","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1128\/AAC.05028-11","article-title":"Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula","volume":"55","author":"Bergen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","article-title":"Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy","volume":"65","author":"Kubin","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0170","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/cid\/cit453","article-title":"Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center","volume":"57","author":"Akajagbor","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0175","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1128\/AAC.00254-13","article-title":"Megalin contributes to kidney accumulation and nephrotoxicity of colistin","volume":"57","author":"Suzuki","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jac\/dkv340","article-title":"Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins","volume":"71","author":"Lu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0185","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.02587-12","article-title":"Polymyxin B induces apoptosis in kidney proximal tubular cells","volume":"57","author":"Azad","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0190","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1152\/physiolgenomics.00076.2013","article-title":"Cell cycle arrest in a model of colistin nephrotoxicity","volume":"45","author":"Eadon","year":"2013","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.medine.2022.08.007_bib0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2018.02.002","article-title":"Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: a systematic review and meta-analysis","volume":"76","author":"Vardakas","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13054-015-0868-y","article-title":"Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis","volume":"19","author":"Zampieri","year":"2015","journal-title":"Critical Care"},{"key":"10.1016\/j.medine.2022.08.007_bib0205","unstructured":"U.S. Food & Drug Administration (FDA). FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics."},{"key":"10.1016\/j.medine.2022.08.007_bib0210","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0215","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2022.08.007_bib0220","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1128\/AAC.00342-13","article-title":"Pharmacodynamics modeling to optimize dosage regimens of sulbactam","volume":"57","author":"Jaruratanasirikul","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0225","doi-asserted-by":"crossref","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.medine.2022.08.007_bib0230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0235","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0240","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0245","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0250","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0255","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1093\/jac\/dku233","article-title":"Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort","volume":"69","author":"L\u00f3pez-Cort\u00e9s","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0260","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0265","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0270","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin resistant Acinetobacter baumannii: a randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.medine.2022.08.007_bib0280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin sulbactam for multiresistant Acinetobacter baumannii ventilator associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.medine.2022.08.007_bib0285","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0290","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ijantimicag.2019.02.016","article-title":"Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and the role of pharmacokinetics\/pharmacodynamics in dose optimization","volume":"53","author":"Lim","year":"2019","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medine.2022.08.007_bib0295","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2-lactamase\u2013producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0300","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.medine.2022.08.007_bib0310","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2022.08.007_bib0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00134-017-5036-1","article-title":"Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM\/ESCMID\/WAAAR round table on multidrug resistance","volume":"44","author":"De Waele","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medine.2022.08.007_bib0320","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1093\/infdis\/jiaa497","article-title":"The gut microbiome as a reservoir for antimicrobial resistance","volume":"223 12 Suppl 2","author":"Anthony","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0325","doi-asserted-by":"crossref","first-page":"336","DOI":"10.12788\/jhm.2905","article-title":"Shorter versus longer courses of antibiotics for infection in hospitalized patients: a systematic review and meta-analysis","volume":"13","author":"Royer","year":"2018","journal-title":"J Hosp Med"},{"key":"10.1016\/j.medine.2022.08.007_bib0330","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/QCO.0000000000000491","article-title":"Optimal duration of antibiotic treatment in Gram-negative infections","volume":"31","author":"De Waele","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0335","doi-asserted-by":"crossref","first-page":"e02495","DOI":"10.1128\/AAC.02495-18","article-title":"Systematic review and meta-analysis of antibiotic treatment duration for bacteremia due to enterobacteriaceae","volume":"63","author":"Tansarli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0340","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10096-019-03467-5","article-title":"Short-versus long-course therapy in gram-negative bacilli bloodstream infections","volume":"38","author":"Sousa","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0345","article-title":"Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults","volume":"2015","author":"Pugh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medine.2022.08.007_bib0350","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2022.08.007_bib0355","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0360","article-title":"Antimicrobial Treatment Duration in Sepsis and Serious Infections","volume":"222 Suppl 2","author":"Busch","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medine.2022.08.007_bib0365","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medine.2022.08.007_bib0370","first-page":"479","article-title":"Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis","volume":"28","author":"Curran","year":"2022","journal-title":"Microbiol Infect"},{"key":"10.1016\/j.medine.2022.08.007_bib0375","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"May","key":"10.1016\/j.medine.2022.08.007_bib0380","article-title":"Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii","author":"Scott","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.medine.2022.08.007_bib0385","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02534-19","article-title":"In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017","volume":"64","author":"McLeod","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.08.007_bib0390","unstructured":"ATTACK Trial. [(Accessed 15 July 2022)]. Available from: https:\/\/investors.entasistx.com\/news-releases\/news-release-details\/entasis-therapeutics-announces-positive-topline-results."}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:36:52Z","timestamp":1761878212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572722002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2173572722002375"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2022.08.007","relation":{},"ISSN":["2173-5727"],"issn-type":[{"value":"2173-5727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Acinetobacter baumannii severe infections","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2022.08.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}